What is Curapel?
Curapel operates at the intersection of biotechnology and consumer health, focusing on patent-protected solutions for conditions such as eczema and psoriasis. The company's product architecture, which includes the Pellamex food supplement and the Pelladerm topical range, is designed to address unmet clinical needs through naturally occurring ingredients. By prioritizing skin barrier function and inflammation management, Curapel has carved out a distinct niche in the dermatology market, moving beyond traditional symptomatic relief toward long-term skin health management. Their strategic focus remains on delivering safe, evidence-based interventions that cater to a growing demographic of patients seeking alternatives to conventional pharmaceutical treatments.
How much funding has Curapel raised?
Curapel has raised a total of $507K across 1 funding round:
Private Equity
$507K
Private Equity (2016): $507K with participation from Lancaster Capital and Finance Wales
Key Investors in Curapel
Lancaster Capital
Lancaster Capital operates as a private investment hub, aggregating capital from successful business leaders to execute strategic equity investments.
Finance Wales
The Development Bank of Wales provides essential equity and loan financing to support regional economic growth, focusing on technology and innovation-led ventures.
What's next for Curapel?
With this major strategic investment, Curapel is well-positioned to accelerate its product development pipeline and expand its market reach. The company's trajectory suggests a shift toward scaling its commercial operations and potentially initiating further clinical trials to validate the efficacy of its proprietary formulations. As the firm matures, the focus will likely transition from early-stage research to broader market penetration, leveraging its existing intellectual property to secure a larger share of the global dermatology market. Continued support from institutional backers will be critical as Curapel navigates the complexities of regulatory approval and international distribution for its specialized skin care portfolio.
See full Curapel company page
